Edward J. Dulac III - 28 Sep 2021 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Financial Officer
Signature
/s/ Cindy Tahl, Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
28 Sep 2021
Net transactions value
-$601,450
Form type
4
Filing time
30 Sep 2021, 16:14:44 UTC
Previous filing
20 Aug 2021
Next filing
22 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $615,384 +17,325 +32% $35.52* 71,864 28 Sep 2021 Direct F1
transaction FATE Common Stock Sale $1,216,834 -19,460 -27% $62.53* 52,404 28 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -17,325 -11% $0.000000 142,675 28 Sep 2021 Common Stock 17,325 $35.52 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.
F2 The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.